Teva considers sale of its active ingredients unit: Bloomberg - YouTube
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva Faces Rocky Path to Recovery After Debt | Fortune
Teva collapse continues on Wall Street - Globes
Teva's Stock Jumps Following Report on Planned Cuts | Ctech
Opioid Epidemic: Drug Wholesalers, Teva Settle With Ohio Counties - Bloomberg
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva (TEVA) Explores Sale of $2 Billion Active Ingredients Unit - Bloomberg
Teva's Adderall Shortage Expected to Continue Into March, FDA Says - BNN Bloomberg
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
Teva Ramps Up Sales With Medis, Respiratory Units - Bloomberg
Teva Earnings Miss by Record - Bloomberg
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
Teva considering potential sale of inflammatory bowel disease asset - Bloomberg
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
Teva mulling bid for Mylan – Bloomberg - Globes
Teva Surges as Buffett's Investment Stokes Hopes of Recovery - Bloomberg
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - BNN Bloomberg
Teva Pharmaceutical Industries Third Quarter 2022 Earnings: Misses Expectations
Teva Cedes Spot as Israel's Biggest Firm in Blow to Prestige - Bloomberg
